Core Insights - Pfizer reported fourth-quarter results that exceeded estimates despite declining demand for Covid products, while reaffirming its modest 2026 guidance that unsettled investors in December [1][5]. Financial Performance - Pfizer's fourth-quarter revenue was $17.56 billion, a decrease of approximately 1% year-over-year, primarily due to reduced demand for its Covid vaccine and Paxlovid [3][10]. - The company recorded a net loss of $1.65 billion, or 29 cents per share, compared to a net income of $410 million, or 7 cents per share, in the same quarter the previous year [4]. - Adjusted earnings per share were reported at 66 cents, surpassing the expected 57 cents [10]. Future Guidance - For 2026, Pfizer expects adjusted profit to range between $2.80 and $3 per share, with revenue projected to be between $59.5 billion and $62.5 billion, indicating flat sales compared to 2025 [5]. - The anticipated decline in revenue includes a projected drop of about $1.5 billion in sales from Covid products, expected to total $5 billion [5][6]. Strategic Initiatives - Pfizer is pursuing long-term investments, including a $10 billion acquisition of obesity biotech Metsera, to mitigate the impact of declining Covid product sales and older drug revenues [2]. - The company aims to cut costs by approximately $7.7 billion by the end of 2027 through two separate initiatives [3]. Market Dynamics - Pfizer faces an expected $1.5 billion year-over-year decline in sales due to certain products losing market exclusivity, with increased competition affecting blockbuster drugs like Prevnar [6]. - The company is also dealing with price and margin compression, as indicated by CFO Dave Denton, due to deeper discounts in its Medicaid business as part of a drug pricing agreement [7]. Regulatory Environment - Under a recent agreement, Pfizer will sell existing drugs to Medicaid patients at the lowest price offered in other developed countries and ensure similar pricing for new drugs for Medicare, Medicaid, and commercial payers, in exchange for a three-year exemption from tariffs [8]. - Pfizer's Xeljanz and Xeljanz XR have been selected for the third round of Medicare drug price negotiations, with new prices set to take effect in 2028 [9].

Core Viewpoint - Merck reported strong fourth-quarter earnings driven by demand for its cancer immunotherapy Keytruda, but provided a modest 2026 outlook that fell short of Wall Street expectations due to upcoming patent expirations and generic competition [1][2]. Financial Performance - For the fourth quarter, Merck posted net income of $2.96 billion, or $1.19 per share, compared to $3.74 billion, or $1.48 per share, in the same period last year [4]. - Adjusted earnings for the fourth quarter were $2.04 per share, slightly above the expected $2.01 per share [6]. - Revenue for the quarter was $16.4 billion, a 5% increase from the previous year, and exceeded expectations of $16.19 billion [5][6]. 2026 Outlook - Merck anticipates 2026 revenue between $65.5 billion and $67 billion, lower than analysts' expectations of $67.6 billion [2]. - The company expects adjusted earnings per share to be between $5 and $5.15, compared to the analyst estimate of $5.36 [2]. Acquisition and Charges - The 2026 guidance includes a one-time charge of approximately $9 billion, or around $3.65 per share, related to the acquisition of Cidara, which is developing a flu prevention drug [3]. Cost Management - Merck is implementing a cost-cutting plan aimed at reducing expenses by $3 billion by the end of 2027 to offset revenue losses from the upcoming patent expiration of Keytruda in 2028 [5]. Drug Pricing Deal - Under a "most favored nation" deal, Merck will sell existing treatments to Medicaid patients at the lowest price offered in other developed nations and will receive a three-year reprieve from tariffs [4].

Core Insights - Pfizer is currently involved in a competitive acquisition battle for Metsera, an obesity drug developer, against Novo Nordisk, with Pfizer's initial offer of approximately $7.3 billion being challenged by Novo Nordisk's increased bid of around $10 billion [2][3][10] - Pfizer has filed lawsuits against Metsera and Novo Nordisk, alleging breach of merger agreement and anticompetitive actions, while seeking to prevent Metsera from terminating the merger agreement [4][5][10] - A recent drug pricing agreement with the Trump administration is seen as a significant milestone for Pfizer, providing clarity on future strategic investments and growth [9][10] Acquisition Battle - Pfizer's definitive agreement to acquire Metsera was announced in September for about $7.3 billion, aiming to re-enter the obesity market after halting the development of danuglipron [2] - Novo Nordisk's unsolicited proposal to acquire Metsera has escalated to a total value of around $10 billion, prompting Pfizer to revise its offer to approximately $8.1 billion [3] - The outcome of the acquisition remains uncertain due to ongoing litigation and counteroffers, with Metsera likely to choose the higher bid [8] Legal Actions - Pfizer has initiated a lawsuit claiming that Metsera breached its merger agreement by considering Novo Nordisk's competing offer, arguing that the latter violates antitrust laws [4] - A second lawsuit was filed against Metsera's directors and Novo Nordisk, labeling the latter's proposal as an anticompetitive move to maintain dominance in the GLP-1 drug market [5] Drug Pricing Agreement - In September, Pfizer signed a drug pricing deal with the Trump administration, agreeing to cut prescription drug prices and align them with those in other developed countries [9] - The agreement includes a three-year exemption from tariffs on pharmaceutical imports in exchange for increased domestic investments, providing long-term clarity for Pfizer's strategic direction [9][11] Financial Performance - Pfizer's stock has declined by 6.3% this year, contrasting with a 7.1% increase in the industry [12] - The company's shares are currently trading at a price/earnings ratio of 8.0, which is lower than the industry average of 15.69 and its own 5-year mean of 10.52 [14] - The Zacks Consensus Estimate for 2025 earnings has increased from $3.05 to $3.11 per share, while the estimate for 2026 has risen from $3.12 to $3.14 per share over the past week [16]

Core Viewpoint - Eli Lilly is set to report its third-quarter results, with significant attention on the potential deal regarding the pricing of its weight-loss drug with the Trump administration [1] Company Summary - Eli Lilly is a drugmaker preparing to announce its financial performance for the third quarter [1] - The company faces uncertainty regarding the negotiations with the Trump administration over the pricing strategy for its weight-loss drug [1] Industry Summary - The pharmaceutical industry is closely monitoring Eli Lilly's upcoming results and the implications of its pricing negotiations, which could set precedents for other companies in the sector [1]